Shots:
The companies have expanded their collaboration on the use of Sirona’s SGLT2 inhibitor, TFC-039 in both animal and human health. The development of TFC-039 as a treatment for diabetes and CKD in companion animals has been discussed by Sirona with animal health companies
In 2014, Wanbang signed a license agreement with Sirona for TFC-039 where Wanbang got the rights to develop the compound as a diabetes treatment in China and Sirona retained the global rights
The companies focus to produce preclinical data, multiple clinical studies, and advancing towards manufacturing development & continues its collaboration with SGLT2 inhibitor along with antiviral and anti-aging projects in 2023
Ref: PRNewswire | Image: Sirona Biochem
